FISCHER CHEMIC LTD.

Fischer Medical Ventures Ltd. announced that its associate company, Nanomedic Technologies Ltd., has received import and distribution approval from India's CDSCO for the Spincare Portable Wound Care System. This is India's first regulatory clearance for a portable electrospun wound care system. Spincare, a Class C medical device, applies a nano-fiber film directly to wounds, eliminating traditional dressings in many cases. The approval positions Fischer Medical Ventures to capitalize on India's growing wound care market, valued at approximately USD 380 million in 2026 and projected to reach USD 1.8 billion by 2033. Fischer holds exclusive distribution rights for India and Southeast Asia. Nanomedic also has a U.S. FDA approval submission in progress.

Fischer Medical Ventures Ltd has announced the closure of its trading window for dealing in the company's equity shares. This closure is in accordance with the company's code of conduct for Prohibition of Insider Trading and SEBI regulations. The window will be shut from July 01, 2026, until 48 hours after the declaration of the Un-Audited Financial Results for the quarter ended June 30, 2026. The company will separately inform stock exchanges about the board meeting to approve these results. Designated persons and their immediate relatives are prohibited from trading during this period.

Fischer Medical Ventures Ltd's board approved audited financial results for the quarter and year ended March 31, 2026, with an unmodified audit opinion from Bilimoria Mehta & Co. They recommended a final dividend of ₹0.05 per equity share, pending AGM approval. S. Ramanand Aiyer & Co. were appointed as internal auditors for FY 2026-27. The Board Meeting commenced at 9.00 PM (IST) and concluded at 11.00 PM (IST).

Fischer Medical Ventures Ltd's board approved the audited financial results for the year ended March 31, 2026. Key highlights include a final dividend recommendation of ₹0.05 per equity share and the appointment of S. Ramanand Aiyer & Co. as internal auditors for FY 2026-27. The company reported revenue from operations of ₹1739.18 lakhs and a loss before tax of ₹1050.58 lakhs for the year ended March 31, 2026.

The Board of Directors of Fischer Medical Ventures Ltd has recommended a final dividend of 5%, which is ₹0.05 per equity share with a face value of Re. 1 each for the financial year ended March 31, 2026. The dividend, if approved at the Annual General Meeting, will be paid/dispatched within 30 days from the date of the AGM.

Fischer Medical Ventures Ltd has scheduled a Board of Directors meeting on May 29, 2026, to consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The board will also consider recommending a dividend, if any. The trading window for dealing in the company's equity shares remains closed until 48 hours after the declaration of the financial results.

Fischer Medical Ventures Ltd. has released a Monitoring Agency Report by Infomerics Valuation and Rating Limited for the quarter ended March 31, 2026, concerning the utilization of funds raised through a preferential share issue. The report, as per SEBI regulations, indicates no deviation from the intended use of the ₹358.46 crore raised. The company has also placed the report on its website.

Fischer Medical Ventures Ltd announces a landmark collaboration between WFNS Innovation & Technology Committee and Time Medical International Ventures (India) Pvt Ltd, a wholly owned subsidiary of Fischer Medical Ventures Limited. The partnership aims to advance global neurosurgical innovation through cutting-edge technologies, training, and knowledge-sharing initiatives. This marks the first time WFNS Innovation & Technology Committee has formally partnered with an industry participant, Time Medical India, to improve patient outcomes worldwide.

Shankar Varadharajan, along with FMV Holdings Pte Ltd and Mr. Ravindran Govindan, have acquired a 0.92% stake in Fischer Medical Ventures Ltd through preferential allotment of warrants. The total equity shares capital of the company after the acquisition stands at Rs. 65,45,15,470 divided into 65,45,15,470 Equity Shares of Re. 1 each.

Fischer Medical Ventures Ltd has allotted 60,00,000 equity shares having a face value of Re. 1/- each at an issue price of Rs. 23.40/- (including a premium of Rs. 22.40 per share) fully paid up. This allotment is pursuant to the conversion of 60,00,000 Convertible Warrants by the Share Warrant Holder, who is a Promoter Category person. The allotment has been made for cash, upon the receipt of the remaining exercise price of Rs. 17.55/- per warrant, aggregating to Rs. 10,53,00,000/-. The allottee is Mr. Shankar Varadharajan, who is a Promoter.